Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Next Deadline
50 days remaining
NOA E-Mailed - SOU Required
Due Date
February 13, 2026
Extension Available
Until August 13, 2026
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 9, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 8, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Aug 8, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 8, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 5, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 5, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Feb 4, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Feb 4, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 2, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 2, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 2, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 13, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 29, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 15, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 14, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 16, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Aug 16, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| May 22, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 22, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 22, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 15, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 22, 2023 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Feb 21, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 15, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Nov 29, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 11, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use
Class 005
Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells
Class 042
Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
Class 044
Medical services; medical information; providing a website featuring medical information
Classification
International Classes
001
005
042
044